SHIFT Newsroom · GLOBAL
Danish cohort study finds no elevated risk of selected vagal-related events
A Danish register study compared people starting GLP-1 medicines with those starting SGLT2 inhibitors for type 2 diabetes, with additional analyses in obesity.
A Danish register study compared people starting GLP-1 medicines with those starting SGLT2 inhibitors for type 2 diabetes, with additional analyses in obesity. It found no elevated risk of the selected outcomes, including fainting, fractures, slow heart rhythms and cardiac-device implantation. These are observational findings about specified outcomes, not proof that all possible risks have been excluded.
SHIFT’s take
Read the study design and limits alongside the finding. This article does not determine individual treatment suitability.